Recent advances in the manipulation of murine gene expression and its utility for the study of human neurological disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 796-807

  Cazzin, Chiara ^a   Ring, Christopher J A ^b  

^a GSK   (Italy)

^b MIDDLESEX UNIVERSITY   (United Kingdom)

Author keywords

Mouse model; Neurological disease; RNA Interference; Viral vector

Indexed keywords

VIRUS VECTOR;

ANIMAL MODEL; GENE EXPRESSION; GENE TRANSFER; GENETIC MANIPULATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; ANIMAL; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MICE; NERVOUS SYSTEM DISEASES;

MURINAE; MUS MUSCULUS;

EID: 77956062964     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.11.005     Document Type: Review

References (114)

1. Oliver P.L., Davies K.E. Analysis of human neurological disorders using mutagenesis in the mouse. Clin. Sci. 2005, 108:385-397.
2. Brusa R. Genetically modified mice in neuropharmacology. Pharmacol. Res. 1999, 39:405-419.
3. Nadeau J.H. Modifier genes in mice and humans. Nat. Rev. Genet. 2001, 2:165-174.
4. Beglopoulos V., Shen J. Gene-targeting technologies for the study of neurological disorders. Neuromol. Med. 2004, 6:13-30.
5. Ristevski S. Making better transgenic models. Mol. Biotechnol. 2005, 29:153-163.
6. Thakker D.R., Hoyer D., Cryan J.F. Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol. Ther. 2006, 109:413-438.
7. Lingor P., Bähr M. Targeting neurological disease with RNAi. Mol. Biosyst. 2007, 11:773-780.
8. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
9. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15:188-200.
10. Grosshans H., Slack F.J. Micro-RNAs: small is plentiful. J. Cell. Biol. 2002, 156:17-21.
11. Coolen M., Bally-Cuif L. MicroRNAs in brain development and physiology. Curr. Opin. Neurobiol. 2009, Oct 19 [Epub ahead of print].
12. Lim L.P., Glasner M.E., Yekta S., Burge C.B., Bartel D.P. Vertebrate microRNA genes. Science 2003, 299:1540.
13. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
14. Olsen L., Klausen M., Helboe L., Nielsen F.C., Werge T. MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats. PLoS One 2009, 4:e7225.
15. De Pietri T.D., Tonelli D., Pulvers J.N., Haffner C., Murchison E.P., Hannon G.J., Huttner W.B. miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development 2008, 135:3911-3921.
16. Kocerha J., Kauppinen S., Wahlestedt C. microRNAs in CNS Disorders. Neuromol. Med. 2009, 11:162-172.
17. Li X., Jin P. Macro role(s) of MicroRNAs in fragile X syndrome?. Neuromol. Med. 2009, 11:200-207.
18. Gomase V.S., Tagore S. RNAi-a tool for target finding in new drug development. Curr. Drug Metab. 2008, 9:241-244.
19. Makimura H., Mizuno T.M., Mastaitis J.W., Agami R., Mobbs C.V. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci. 2002, 3:18.
20. Hassani Z., Lemkine G.F., Erbacher P., Palmier K., Alfama G., Giovannangeli C., Behr J.P., Demeneix B.A. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 2005, 7:198-207.
21. Bergen J.M., Park I.K., Horner P.J., Pun S.H. Nonviral approaches for neuronal delivery of nucleic acids. Pharm. Res. 2008, 25:983-998.
22. Peters M., Bletsch M., Catapano R., Zhang X., Tully T., Bourtchouladze R. RNA interference in hippocampus demonstrates opposing roles for CREB and PP1alpha in contextual and temporal long-term memory. Genes Brain Behav. 2009, 8:320-329.
23. Lingor P., Bähr M. Targeting neurological disease with RNAi. Mol. Biosyst. 2007, 3:773-780.
24. Akaneya Y., Jiang B., Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J. Neurophysiol. 2005, 93:594-602.
25. Thakker D.R., Natt F., Hüsken D., Maier R., Müller M., van der Putten H., Hoyer D., Cryan J.F. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17270-17275.
26. Thakker D.R., Natt F., Hüsken D., van der Putten H., Maier R., Hoyer D., Cryan J.F. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 2005, 10:782-789.
27. Fendt M., Schmid S., Thakker D.R., Jacobson L.H., Yamamoto R., Mitsukawa K., Maier R., Natt F., Hüsken D., Kelly P.H., McAllister K.H., Hoyer D., van der Putten H., Cryan J.F., Flor P.J. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol. Psychiatry 2008, 13:970-979.
28. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
29. Cryan J.F., Thakker D.R., Hoyer D. Emerging use of non-viral RNA interference in the brain. Biochem. Soc. Trans. 2007, 35:411-415.
30. Christoph T., Grünweller A., Mika J., Schäfer M.K., Wade E.J., Weihe E., Erdmann V.A., Frank R., Gillen C., Kurreck J. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem. Biophys. Res. Commun. 2006, 350:238-243.
31. Yu J.Y., Wang T.W., Vojtek A.B., Parent J.M., Turner D.L. Use of short hairpin RNA expression vectors to study mammalian neural development. Methods Enzymol. 2005, 392:186-199.
32. Scherr M., Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell. Cycle 2007, 6:444-449.
33. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C., Rao J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem. 2005, 280:21882-21892.
34. Pardridge W.M. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert. Opin. Biol. Ther. 2004, 4:1103-1113.
35. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., Pardridge W.M., Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 2004, 10:3667-3677.
36. Lundberg C., Bjorklund T., Carlsson T., Jakobsson J., Hantraye P., Deglon N., Kirik D. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 2008, 8:461-473.
37. Van den Haute C., Eggermont K., Nuttin B., Debyser Z., Baekelandt V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum. Gene Ther. 2003, 14:1799-1807.
38. Ren G., Li T., Lan J.Q., Wilz A., Simon R.P., Boison D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp. Neurol. 2007, 208:26-37.
39. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., Hjelmeland A.B., Rich J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008, 68:6043-6048.
40. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 2002, 20:1006-1010.
41. Hommel J.D., Sears R.M., Georgescu D., Simmons D.L., DiLeone R.J. Local gene knockdown in the brain using viral-mediated RNA interference. Nat. Med. 2003, 9:1539-1544.
42. Farah M.H. RNAi silencing in mouse models of neurodegenerative diseases. Curr. Drug Del. 2007, 4:161-167.
43. Raoul C., Barker S.D., Aebischer P. Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther. 2006, 13:487-495.
44. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 2005, 11:423-428.
45. Azzouz M., Mazarakis N. Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases. Curr. Gene Ther. 2004, 4:277-286.
46. Miller T.M., Kaspar B.K., Kops G.J., Yamanaka K., Christian L.J., Gage F.H., Cleveland D.W. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57:773-776.
47. Towne C., Raoul C., Schneider B.L., Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol. Ther. 2008, 16:1018-1025.
48. Machida Y., Okada T., Kurosawa M., Oyama F., Ozawa K., Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 2006, 343:190-197.
49. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 2005, 102:5820-5825.
50. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
51. Wong H.K., Bauer P.O., Kurosawa M., Goswami A., Washizu C., Machida Y., Tosaki A., Yamada M., Knöpfel T., Nakamura T., Nukina N. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum. Mol. Genet. 2008, 17:3223-3235.
52. Xia H., Mao Q., Eliason S.L., Harper S.Q., Martins I.H., Orr H.T., Paulson H.L., Yang L., Kotin R.M., Davidson B.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 2004, 10:816-820.
53. Hong C.S., Goins W.F., Goss J.R., Burton E.A., Glorioso J.C. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther. 2006, 13:1068-1079.
54. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., Verma I.M., Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 2008, 8:1343-1349.
55. AbdAlla S., Lother H., el Missiry A., Langer A., Sergeev P., el Faramawy Y., Quitterer U. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J. Biol. Chem. 2009, 284:6554-6565.
56. Manfredsson F.P., Lewin A.S., Mandel R.J. RNA knockdown as a potential therapeutic strategy in Parkinson's disease. Gene Ther. 2006, 13:517-524.
57. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
58. Snøve O.J., Rossi J.J. Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol. 2006, 7:231.
59. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5868-5873.
60. Carmell M.A., Zhang L., Conklin D.S., Hannon G.J., Rosenquist T.A. Germline transmission of RNAi in mice. Nat. Struct. Biol. 2003, 10:91-92.
61. Rubinson D.A., Dillon C.P., Kwiatkowski A.V., Sievers C., Yang L., Kopinja J., Rooney D.L., Zhang M., Ihrig M.M., McManus M.T., Gertler F.B., Scott M.L., Van Parijs L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33:401-406.
62. Singer O., Verma I.M. Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr. Gene Ther. 2008, 8:483-488.
63. Szulc J., Wiznerowicz M., Sauvain M.O., Trono D., Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat. Methods 2006, 3:109-116.
64. Zhou H., Falkenburger B.H., Schulz J.B., Tieu K., Xu Z., Xia X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int. J. Biol. Sci. 2007, 3:242-250.
65. Walther W., Stein U. Viral vectors for gene transfer. Drugs 2000, 60:249-271.
66. Schnell M.A., Zhang Y., Tazelaar J., Gao G.P., Yu Q.C., Qian R., Chen S.J., Varnavski A.N., LeClair C., Raper S.E., Wilson J.M. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 2001, 3:708-722.
67. Rainov N.G., Kramm C.M. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr. Gene Ther. 2001, 1:367-383.
68. St Martin J.L., Klucken J., Outeiro T.F., Nguyen P., Keller-McGandy C., Cantuti-Castelvetri I., Grammatopoulos T.N., Standaert D.G., Hyman B.T., McLean P.J. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 2007, 100:1449-1457.
69. Wenzel H.J., Vacher H., Clark E., Trimmer J.S., Lee A.L., Sapolsky R.M., Tempel B.L., Schwartzkroin P.A. Structural consequences of Kcna1 gene deletion and transfer in the mouse hippocampus. Epilepsia 2007, 48:2023-2046.
70. Alerte T.N., Akinfolarin A.A., Friedrich E.E., Mader S.A., Hong C.S., Perez R.G. α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neurosci. Lett. 2008, 435:24-29.
71. Young L.S., Searle P.F., Onion D., Mautner V. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 2006, 208:299-318.
72. McBride J.L., Ramaswamy S., Gasmi M., Bartus R.T., Herzog C.D., Brandon E.P., Zhou L., Pitzer M.R., Berry-Kravis E.M., Kordower J.H. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U S A. 2006, 103:9345-9350.
73. Kells A.P., Fong D.M., Dragunow M., During M.J., Young D., Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington's disease. Molec. Ther. 2004, 9:682-688.
74. Bensadoun J.C., Déglon N., Tseng J.L., Ridet J.L., Zurn A.D., Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 2000, 164:15-24.
75. Ridet J.L., Bensadoun J.C., Déglon N., Aebischer P., Zurn A.D. Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease. Neurobiol. Dis. 2006, 21:29-34.
76. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18757-18762.
77. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., Kim S.H., Kaspar R., Taksir T.V., Griffiths D.A., Cheng S.H., Shihabuddin L.S., Kaspar B.K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 2008, 16:1056-1064.
78. Chu Q., Moreland R., Yew N.S., Foley J., Ziegler R., Scheule R.K. Systemic Insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol. Ther. 2008, 16:1400-1408.
79. Odom G.L., Gregorevic P., Chamberlain J.S. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim. Biophys. Acta 2007, 1772:243-262.
80. Nishiyama A., Ampong B.N., Ohshima S., Shin J.H., Nakai H., Imamura M., Miyagoe-Suzuki Y., Okada T., Takeda S. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice. Hum. Gene Ther. 2008, 19:719-730.
81. Fu H., Kang L., Jennings J.S., Moy S.S., Perez A., Dirosario J., McCarty D.M., Muenzer J. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther. 2007, 14:1065-1077.
82. Cachón-González M.B., Wang S.Z., Lynch A., Ziegler R., Cheng S.H., Cox T.M. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10373-10378.
83. Martino S., Marconi P., Tancini B., Dolcetta D., Cusella De Angelis M.G., Montanucci P., Bregola G., Sandhoff K., Bordignon C., Emiliani C., Manservigi R., Orlacchio A. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum. Mol. Genet. 2005, 14:2113-2123.
84. Dodge J.C., Clarke J., Song A., Bu J., Yang W., Taksir T.V., Griffiths D., Zhao M.A., Schuchman E.H., Cheng S.H., O'Riordan C.R., Shihabuddin L.S., Passini M.A., Stewart G.R. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17822-17827.
85. Benítez J.A., Domínguez-Monzón G., Segovia J. Conventional and gene therapy strategies for the treatment of brain tumors. Curr. Med. Chem. 2008, 15:729-742.
86. Abe T., Terada K., Wakimoto H., Inoue R., Tyminski E., Bookstein R., Basilion J.P., Chiocca E.A. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 2003, 63:2300-2305.
87. Zamorano A., Mellstrom B., Vergara P., Naranjo J.R., Segovia J. Glial-specific retrovirally mediated gas1 gene expression induces glioma cell apoptosis and inhibits tumor growth in vivo. Neurobiol. Dis. 2004, 3:483-491.
88. Benítez J.A., Arregui L., Vergara P., Segovia J. Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas. Cancer Gene Ther. 2007, 10:836-846.
89. Harding T.C., Lalani A.S., Roberts B.N., Yendluri S., Luan B., Koprivnikar K.E., Gonzalez-Edick M., Huan-Tu G., Musterer R., VanRoey M.J., Ozawa T., LeCouter R.A., Deen D., Dickinson P.J., Jooss K. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol. Ther. 2006, 5:956-966.
90. Prabhakar S., Messerli S.M., Stemmer-Rachamimov A.O., Liu T.C., Rabkin S., Martuza R., Breakefield X.O. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007, 5:460-467.
91. Liu T.C., Zhang T., Fukuhara H., Kuroda T., Todo T., Canron X., Bikfalvi A., Martuza R.L., Kurtz A., Rabkin S.D. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin. Cancer Res. 2006, 12:6791-6799.
92. Buning H., Nicklin S.A., Perabo L., Hallek M., Baker A.H. AAV-based gene transfer. Curr. Opin. Mol. Ther. 2003, 5:367-375.
93. Lo W.D., Qu G., Sferra T.J., Clark R., Chen R., Johnson P.R. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther. 1999, 10:201-213.
94. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol. Psychiatry 2008, 63:642-649.
95. Fukushima F., Nakao K., Shinoe T., Fukaya M., Muramatsu S., Sakimura K., Kataoka H., Mori H., Watanabe M., Manabe T., Mishina M. Ablation of NMDA receptors enhances the excitability of hippocampal CA3 neurons. PLoS One 2009, 4:e3993.
96. Lim F., Palomo G.M., Mauritz C., Giménez-Cassina A., Illana B., Wandosell F., Díaz-Nido J. Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol. Ther. 2007, 15:1072-1078.
97. Lamb B.T., Gearhart J.D. YAC transgenics and the study of genetics and human disease. Curr. Opin. Genet. and Dev. 1995, 5:342-348.
98. Giraldo P., Montoliu L. Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res. 2001, 10:83-103.
99. Van Raamsdonk J.M., Warby S.C., Hayden M.R. Selective degeneration in YAC mouse models of Huntington disease. Brain Res. Bull. 2007, 72:124-131.
100. Zhang H., Li Q., Graham R.K., Slow E., Hayden M.R., Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 2008, 31:80-88.
101. Cowan C.M., Fan M.M., Fan J., Shehadeh J., Zhang L.Y., Graham R.K., Hayden M.R., Raymond L.A. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J. Neurosci. 2008, 28:12725-12735.
102. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
103. Moseley M.L., Zu T., Ikeda Y., Gao W., Mosemiller A.K., Daughters R.S., Chen G., Weatherspoon M.R., Clark H.B., Ebner T.J., Day J.W., Ranum L.P. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 2006, 38:758-769.
104. Chen X., Tang T.S., Tu H., Nelson O., Pook M., Hammer R., Nukina N., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 2008, 28:12713-12724.
105. Kulnane L.S., Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol. Dis. 2001, 8:982-992.
106. Lu X.H., Fleming S.M., Meurers B., Ackerson L.C., Mortazavi F., Lo V., Hernandez D., Sulzer D., Jackson G.R., Maidment N.T., Chesselet M.F., Yang X.W. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J. Neurosci. 2009, 29:1962-1976.
107. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., O'Dell T.J., Fung J., Weier H.U., Cheng J.F., Rubin E.M. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 1997, 16:28-36.
108. Ahn K.J., Jeong H.K., Choi H.S., Ryoo S.R., Kim Y.J., Goo J.S., Choi S.Y., Han J.S., Ha I., Song W.J. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 2006, 22:463-472.
109. van der Staay F.J., Steckler T. Behavioural phenotyping of mouse mutants. Behav. Brain Res. 2001, 125:3-12.
110. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997, 132:107-124.
111. Hafezparast M., Ahmad-Annuar A., Wood N.W., Tabrizi S.J., Fisher E.M. Mouse models for neurological disease. Lancet Neurol. 2002, 1:215-224.
112. Matthaei K.I. Genetically manipulated mice: a powerful tool with unsuspected caveats. J. Physiol. 2007, 582:481-488.
113. Lamb B.T., Bardel K.A., Kulnane L.S., Anderson J.J., Holtz G., Wagner S.L., Sisodia S.S., Hoeger E.J. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 1999, 2:695-697.
114. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 2000, 7:87-98.